摘要目的:探讨基于二代测序检测技术下的克隆性基因突变对第1次完全缓解（CR 1）状态下接受高剂量化疗或自体造血干细胞移植（强化巩固治疗）的RUNX1-RUNX1T1融合基因阳性急性髓系白血病（AML）预后的影响。 方法:收集2011年7月至2017年8月在苏州大学附属第一医院CR 1状态下接受强化巩固治疗的79例RUNX1-RUNX1T1融合基因阳性AML患者的临床资料，通过Kaplan-Meier曲线、Cox回归模型分析临床因素及突变基因对患者总生存（OS）和无病生存（DFS）时间的影响。 结果:在79例患者中，检出C-KIT、FLT3、CEBPA、DNMT3A基因突变者分别为25例（31.6%）、6例（7.6%）、8例（8.9%）、1例（1.3%），其中C-KIT exon17及C-KIT exon8突变分别为19例（24.1%）、5例（6.3%），FLT3-ITD突变为5例（6.3%）。初诊白细胞计数越高，患者的OS时间越短（ P=0.030），合并C-KIT exon17突变患者的OS时间（ P=0.010）和DFS时间（ P=0.006）明显缩短，合并FLT3-ITD基因突变患者的OS时间（ P=0.048）和DFS时间（ P=0.071）缩短。多因素分析显示合并C-KIT exon17和FLT3-ITD突变均为影响患者预后的独立因素。 结论:在接受强化巩固治疗的RUNX1-RUNX1T1融合基因阳性AML患者中，C-KIT exon 17、FLT3-ITD基因突变提示预后较差，这将对细化患者危险度分层、个体化治疗、评估预后有指导意义。

abstractsObjective:To investigate the prognostic value of clonal gene mutations detected by second-generation sequencing in patients with positive RUNX1-RUNX1T1 acute myeloid leukemia (AML) who received high-dose chemotherapy or autologous transplantation (intensive consolidation therapy) in the first complete remission (CR 1) state. Methods:79 AML patients with positive RUNX1-RUNX1T1 who received intensive consolidation therapy in CR 1 state from July 2011 to August 2017 were analyzed retrospectively. Kaplan-Meier curve and Cox regression model were used to figure out the effect of leukocyte counts at onset and gene mutations for prognosis. Results:C-KIT, FLT3, CEBPA and DNMT3A gene mutations were found in 25 (31.6%) , 6 (7.6%) , 7 (8.9%) and 1 (1.3%) patient among the population. Mutations in C-KIT exon17 and C-KIT exon8 were detected in 19 (24.1%) and 5 (6.3%) cases, respectively, and mutations of FLT3-ITD were confirmed in 5 (6.3%) cases. The higher leukocyte counts presented at onset of leukemia, the shorter overall survival (OS) was seen in these patients ( P=0.03) . Patients with C-KIT exon17 mutation had significantly shorter OS ( P=0.01) and disease free survival (DFS) ( P=0.006) compared with those without gene mutations, and patients with FLT3-ITD gene mutation got the inferior OS ( P=0.048) and DFS ( P=0.071) . Conclusion:In AML patients with positive RUNX1-RUNX1T1 receiving intensive consolidation therapy, the white blood cell counts at onset of leukemia, C-KIT mutations in exon 17, and FLT3-ITD gene mutations suggest poor prognosis, which would contribute to elaborate risk stratification, personalized treatment and predict prognosis for these patients.